文献速递淋巴瘤

诊断时可检测到的单克隆蛋白对边缘区淋巴瘤结局的影响:一项多中心队列研究

Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.
PubMed 文献 · Blood Adv · 2023-01-01

这项多中心回顾性队列纳入547例接受一线治疗的边缘区淋巴瘤患者,173例(32%)诊断时可检测到M蛋白。调整混杂因素后,M蛋白的存在仍与更差的PFS独立相关(HR 1.74,95%CI 1.20-2.54,P=.004)。接受苯达莫司汀联合利妥昔单抗的患者中未观察到该PFS差异,作者认为免疫化疗可能优于利妥昔单抗单药,需进一步探索。

要点

  • 547例MZL患者中173例(32%)诊断时可检测到M蛋白。
  • 诊断时M蛋白与更差PFS独立相关(HR 1.74,95%CI 1.20-2.54,P=.004)。
  • 接受苯达莫司汀联合利妥昔单抗者中未观察到M蛋白相关的PFS差异。

核心结论

  • 诊断时存在M蛋白与MZL患者更差的PFS独立相关(HR 1.74,95%CI 1.20-2.54,P=.004)。
  • 诊断时M蛋白与更高的组织学转化风险相关。
  • 在接受苯达莫司汀联合利妥昔单抗的患者中未观察到M蛋白相关的PFS差异。
  • 作者认为在该组患者中免疫化疗可能优于利妥昔单抗单药,需进一步探索。

研究设计与样本

  • 多中心回顾性队列研究。
  • 纳入547例接受一线治疗的边缘区淋巴瘤患者。

主要发现

  • 173例(32%)患者诊断时可检测到M蛋白。
  • M蛋白组与无M蛋白组从诊断到开始任何治疗(全身和局部)的时间无显著差异。
  • 诊断时M蛋白组PFS显著劣于无M蛋白组。
  • 调整与PFS劣化相关的因素后,M蛋白的存在仍与更差PFS显著相关(HR 1.74,95%CI 1.20-2.54,P=.004)。
  • 基于诊断时M蛋白类型或数量的PFS无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Given the paucity of data surrounding the prognostic relevance of monoclonal paraprotein (M-protein) in marginal zone lymphoma (MZL), we sought to evaluate the impact of detecting M-protein at diagnosis on outcomes in patients with MZL in a large retrospective cohort. The study included 547 patients receiving first-line therapy for MZL. M-protein was detectable at diagnosis in 173 (32%) patients. There was no significant difference in the time from diagnosis to initiation of any therapy (systemic and local) between the M-protein and no M-protein groups. Patients with M-protein at diagnosis had significantly inferior progression-free survival (PFS) compared with those without M-protein at diagnosis. After adjusting for factors associated with inferior PFS in univariate models, presence of M-protein remained significantly associated with inferior PFS (hazard ratio, 1.74; 95% confidence interval, 1.20-2.54; P = .004). We observed no significant difference in the PFS based on the type or quantity of M-protein at diagnosis. There were differential outcomes in PFS based on the first-line therapy in patients with M-protein at diagnosis, in that, those receiving immunochemotherapy had better outcomes compared with those receiving rituximab monotherapy. The cumulative incidence of relapse in stage 1 disease among the recipients of local therapy was higher in the presence of M-protein; however, this did not reach statistical significance. We found that M-protein at diagnosis was associated with a higher risk of histologic transformation. Because the PFS difference related to presence of M-protein was not observed in patients receiving bendamustine and rituximab, immunochemotherapy may be a preferred approach over rituximab monotherapy in this group and needs to be explored further.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Epperla N, Zhao Q, Karmali R, et al. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood Adv. 2023. PMID: 37315169. doi:10.1182/bloodadvances.2023010133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。